North America Circulating Tumor Cell (CTC) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CTC Detection and Enrichment Method, CTC Direct Detection Method, and CTC Analysis), Application (Clinical/Liquid Biopsy,

North America Circulating Tumor Cell (CTC) Diagnostics Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Technology (CTC Detection and Enrichment Method, CTC Direct Detection Method, and CTC Analysis), Application (Clinical/Liquid Biopsy, and Research), and End-User (Hospitals and Clinics, Research and Academic Institutes, and Diagnostic Centers)

The North America circulating tumor cell (CTC) diagnostics market is expected to reach US$ 1,664.0 million by 2028 from US$ 861.6 million in 2021. The market is estimated to grow at a CAGR of 9.9% from 2021 to 2028.

Health systems in this region are witnessing a substantial increase in the prevalence of cancer. According to the International Agency for Research on Cancer (IARC), cancer burden in North America has increased to 19.3 million cases and 9.96 million cancer deaths as of 2020. A study published by the National Cancer Institute estimated the cancer incidence in the US at 1.9 million in 2021. ~0.6 million people were anticipated to die in 2021 in the US due to cancer. Thus, the increased prevalence of cancer across North America is propelling the demand for circulating tumor cell (CTC) diagnostics. The analysis and detection of circulating tumor cells assist in early patient diagnosis, and prognosis helps determine accurate treatment for the patient. The CTC diagnostics can be used to detect various types of cancers, including prostate cancer, breast cancer, colorectal cancer, kidney cancer, lymphomas, lung cancer, and melanoma. There has been a high demand for CTC diagnostics in recent years due to its reliability and accuracy in identifying the risk of the disease and monitoring its treatments.

The impact of the COVID-19 pandemic on cancer patients, cancer surveillance capacities, and the whole American health system has been notable. Reduced resources and limited healthcare capacity made cancer detection and treatment more difficult, resulting in lower incidence, higher mortality, and lower survival in the future. Because of a compromised immune system caused by cancer and/or its treatment (e.g., surgery and chemotherapy), people with active cancer are more susceptible to infectious pathogens. Thus, the risk of COVID-19 severity and mortality may be more common in cancer patients. Males; people of age 60 and above; people with a history of smoking; populations suffering from obesity, hypertension, cardiovascular disease, and diabetes have all been consistently related to an elevated risk of severe disease and/or death. Findings relating to prognosis for cancer-associated variables have proven conflicting.

With new features and technologies, vendors can attract new customers and expand their footprints in emerging markets. This factor is likely to drive the circulating tumor cell (CTC) diagnostics market in North America at a good CAGR during the forecast period.

North America Circulating Tumor Cell (CTC) Diagnostics Market Revenue and Forecast to 2028 (US$ Million)

North America Circulating Tumor Cell (CTC) Diagnostics Market Segmentation

By Technology

CTC detection and Enrichment Method CTC Direct Detection Methods CTC Analysis

By Application

Clinical/Liquid Biopsy Risk Assessment Screening and Monitoring Research Cancer Stem Cell and Tumorigenesis Research Drug/Therapy Development

By End-User

Hospitals and Clinics Research and Academic Institutes Diagnostic Centers

By Country

US Canada Mexico

Companies Mentioned

Thermo Fisher Scientific Inc. Stemcell Technologies Inc. Qiagen Precision Medicine Group, Llc Advanced Cell Diagnostics, Inc. (Bio-Techne Corporation) Epic Lifesciences Screencell Ikonisys, Inc IVdiagnostics Fluxion Biosciences

Reasons to Buy

Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the North America circulating tumor cell (CTC) diagnostics market.
Highlights key business priorities in order to assist companies to realign their business strategies.
The key findings and recommendations highlight crucial progressive industry trends in the North America circulating tumor cell (CTC) diagnostics market, thereby allowing players across the value chain to develop effective long-term strategies.
Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
Scrutinize in-depth global market trends and outlook coupled with the factors driving the market, as well as those hindering it.
Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.